Tülay Kuş
About
In The Last Decade
Tülay Kuş
41 papers receiving 406 citations
Peers
Comparison fields: 5 of 69
- Oncology 260
- Surgery 133
- Cancer Research 77
- Pulmonary and Respiratory Medicine 73
- Radiology, Nuclear Medicine and Imaging 66
Countries citing papers authored by Tülay Kuş
This map shows the geographic impact of Tülay Kuş's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tülay Kuş with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tülay Kuş more than expected).
Fields of papers citing papers by Tülay Kuş
This network shows the impact of papers produced by Tülay Kuş. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tülay Kuş. The network helps show where Tülay Kuş may publish in the future.
Co-authorship network of co-authors of Tülay Kuş
This figure shows the co-authorship network connecting the top 25 collaborators of Tülay Kuş. A scholar is included among the top collaborators of Tülay Kuş based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tülay Kuş. Tülay Kuş is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 0 | |
| 2 | 1 | |
| 3 | 22 | |
| 4 | 1 | |
| 5 | 1 | |
| 6 | 1 | |
| 7 | 30 | |
| 8 | 2 | |
| 9 | 72 | |
| 10 | 10 | |
| 11 | Long-term survival with transarterial chemoembolization and radioembolization in a patient with cancers of unknown primary | 1 |
| 12 | 4 | |
| 13 | 23 | |
| 14 | Survival analysis in second-line and third-line chemotherapy with irinotecan followed by topotecan or topotecan followed by irinotecan for extensive-stage small-cell lung cancer patients: a single-center retrospective study | 2 |
| 15 | 1 | |
| 16 | 5 | |
| 17 | 11 | |
| 18 | 1 | |
| 19 | 17 | |
| 20 | 7 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.